ICON (NASDAQ: ICLR) — Perfil da empresa, notícias e dados financeiros
ICON provides outsourced development and commercialization services to healthcare organizations, focusing on clinical trials.
ICON
ICON is a global contract research organization (CRO) that provides outsourced drug and medical device development services to the pharmaceutical, biotechnology, and medical device industries. Headquartered in Dublin, Ireland, the company offers a comprehensive range of clinical, consulting, and commercial services across all phases of clinical development. Its capabilities encompass early-stage clinical trial management, laboratory testing, biostatistical analysis, regulatory affairs, patient recruitment, decentralized clinical trials, and real-world evidence solutions. Operating internationally across Europe, the Americas, and Asia-Pacific, ICON assists sponsors in advancing therapies and medical technologies from conceptual research through regulatory approval and commercial distribution.
Resumo
Operações
Produtos e/ou serviços de ICON
- Clinical Trial Management: Comprehensive management of Phase I through Phase IV global clinical trials across therapeutic areas such as oncology, cardiovascular, central nervous system, and infectious diseases, managing investigator sites, monitoring operations, and data management globally.
- Early Clinical & Bioanalytical Solutions: Execution of early-phase clinical studies and bioanalytical laboratory services, operating dedicated clinical research units and bioanalytical facilities to evaluate drug safety, pharmacokinetics, pharmacodynamics, and biomarker analysis for initial biopharmaceutical candidate testing.
- Specialty Laboratory Solutions: Central and specialty laboratory services supporting precision medicine programs across clinical development stages, delivering bioanalytical testing, flow cytometry, anatomical pathology, genomic testing, and central biomarker assay execution across global site networks.
- Consulting & Commercial Solutions: Strategic advisory and commercialization services covering health economics, outcome measures, pricing and market access, regulatory intelligence, asset development consulting, and real-world evidence generation for pharmaceutical and medical device sponsors.
- Site & Patient Solutions: Integrated patient recruitment, retention, and investigator site network support, deploying targeted engagement strategies, clinical trial site management, and real-time patient enrollment data systems across primary research hubs globally.
- Decentralised & Digital Clinical Trials: Digital research tools and remote clinical trial capabilities including home health services, direct-to-patient supply logistics, remote patient monitoring equipment, and integrated data integration platforms connecting clinical trial participants worldwide.
equipe executiva do ICON
- Barry BalfeCEO & Director
- John ClimaxFounder & Independent Non-Executive Director
- Nigel ClerkinChief Financial Officer
- Steve EmpolitiChief Commercial Officer
- Lyons EmerChief Accounting Officer
- Thomas N. O'LearyChief Information Officer
- Diarmaid CunninghamChief Administrative Officer, General Counsel & Company Secretary
- Niamh MurphyDirector of Corporate Communications
- David GreenVice President of Marketing
- Joe CroninChief Human Resources Officer
Últimas notícias sobre a ICON
Principais indicadores financeiros
Resultados divulgados pela ICON , em USD.
- Cap. de mercado
- 16,5 bi
- Receita (TTM)
- 8,3 bi
- P/L
- 85.7
- LPA (diluído, TTM)
- 2.5
- Dividend yield
- —
- Margem de lucro
- 0.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 8,3 bi | 1 bi | 229,3 mi | |
| 8,3 bi | 1,1 bi | 791,5 mi | |
| 8,1 bi | 956,2 mi | 612,3 mi | |
| 7,7 bi | 795,2 mi | 505,3 mi |